Current clinically used tumor markers for GC screening have achieved much progress, including HER267, human epidermal growth factor receptor (EGFR)68, mammalian target of rapamycin (mTOR)69, PD-L170,71, and TP5322. This evidence concerns the gene MTOR and neoplasm.